Development, characterizations and biocompatibility evaluations of intravitreal lipid implants

Jundishapur Journal of Natural Pharmaceutical Products

Volumn 9, Issue 2, 2014, Pages

  Tamaddon, Lana ^a   Mostafavi, Abolfazl ^a   Riazi Esfahani, Mohammad ^b   Karkhane, Reza ^b   Aghazadeh, Sara ^b   Rafiee Tehrani, Morteza ^c   Dorkoosh, Farid Abedin ^c   Amoli, Fahimeh Asadi ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Disease; Toxicology; Triglyceride

Indexed keywords

CLINDAMYCIN PHOSPHATE; DRUG CARRIER; TRIPALMITIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B WAVE; BIOCOMPATIBILITY; BLEEDING; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DARK ADAPTATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; RABBIT; RETINAL THICKNESS;

EID: 84899858922     PISSN: 17357780     EISSN: 22287876     Source Type: Journal    
DOI: 10.17795/jjnpp-16414     Document Type: Article

References (14)

1. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci. 2010;99(5):2219-39.
2. Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 2001;215(3):143-55.
3. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/ polyglycolic acid copolymers. Biomaterials. 1996;17(2):93-102.
4. Guse C, Koennings S, Maschke A, Hacker M, Becker C, Schreiner S, et al. Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. Int J Pharm. 2006;314(2):153-60.
5. Reitz C, Kleinebudde P. Solid lipid extrusion of sustained release dosage forms. Eur J Pharm Biopharm. 2007;67(2):440-8.
6. Vogelhuber W, Magni E, Mouro M, Spruss T, Guse C, Gazzaniga A, et al. Monolithic triglyceride matrices: a controlled-release system for proteins. Pharm Dev Technol. 2003;8(1):71-9.
7. Lucke A, Kiermaier J, Gopferich A. Peptide acylation by poly(alpha-hydroxy esters). Pharm Res. 2002;19(2):175-81.
8. Koennings S, Sapin A, Blunk T, Menei P, Goepferich A. Towards controlled release of BDNF--manufacturing strategies for protein- loaded lipid implants and biocompatibility evaluation in the brain. J Control Release. 2007;119(2):163-72.
9. Reithmeier H, Herrmann J, Gopferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release. 2001;73(2):339-50.
10. Koennings S, Garcion E, Faisant N, Menei P, Benoit JP, Goepferich A. In vitro investigation of lipid implants as a controlled release system for interleukin-18. Int J Pharm. 2006;314(2):145-52.
11. Appel B, Maschke A, Weiser B, Sarhan H, Englert C, Angele P, et al. Lipidic implants for controlled release of bioactive insulin: effects on cartilage engineered in vitro. Int J Pharm. 2006;314(2):170-8.
12. Reithmeier H, Herrmann J, Gopferich A. Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int J Pharm. 2001;218(1-2):133-43.
13. Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina. 2007;27(7):952-7.
14. Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134-41.